EMD Serono is the biopharmaceutical healthcare business of Merck KGaA, Darmstadt, Germany, operating primarily in the United States and Canada. It focuses on developing innovative therapies for difficult-to-treat conditions such as multiple sclerosis, infertility, and cancer, with core expertise in neurology, endocrinology, oncology, immuno-oncology, and immunology[2][6]. The company is known for its commitment to groundbreaking science and patient-centered care, supporting around 2 million people through patient assistance programs and employing approximately 1,000 people in the U.S.[6]. The roots of EMD Serono trace back to 1668, when Friedrich Jacob Merck acquired the Angel Pharmacy in Darmstadt, Germany, marking the beginning of the world's oldest pharmaceutical and chemical company[3][5]. Over centuries, Merck evolved from a manual pharmacy craft to a global industrial research company under Emanuel Merck's leadership in the early 19th century, expanding internationally, including establishing a U.S. presence in 1887[3][5]. In parallel, Serono was founded in 1906 in Rome by Cesare Serono as the Serono Pharmacological Institute, pioneering extraction methods for urinary gonadotropins crucial for reproductive health treatments[1][7]. Serono was acquired by Merck in 2006, integrating its expertise in reproductive health, neurology, dermatology, and growth metabolism with Merck’s global capabilities[1][8]. This merger enhanced research in oncology and autoimmune diseases and led to significant advancements in biotechnology such as massive parallel sequencing technologies[1]. Today, EMD Serono continues this legacy, leveraging Merck’s 350-year heritage and global resources to innovate in healthcare, delivering eight marketed drugs in the U.S. with six FDA approvals since 2017, and aiming to double R&D productivity in its core areas[6]. Notably, EMD Serono operates withi